Drug Trial Radar · NCT05132127
Sutimlimab (BIVV009) for the Adult Participants With Cold Agglutinin Disease (CAD) Who Have Completed Phase 3 Studies (CARDINAL or CADENZA) in Japan
Last checked: Nov 20, 2026Latest source record: Sep 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
7
Actual
Start
Nov 11, 2021
Primary completion
Nov 15, 2022
Study completion Nov 15, 2022
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Nov 24, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a multi-center, single treatment-group, open-label study to provide sutimlimab to the adult participants with cold agglutinin disease (CAD) who had completed the CARDINAL (NCT number: NCT03347396) or CADENZA (NCT number: NCT03347422) studies and benefitted from sutimlimab treatment in Japan. • Study and treatment duration: the period between the participant's completion of the CARDINAL and CADENZA studies and sutimlimab or other appropriate CAD therapy becoming commercially available to participants in Japan.
Conditions
- Cold Agglutinin Disease
Interventions
sutimlimabDrug
Pharmaceutical form: solution for injection Route of administration: intravenous (IV)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)Time frame: From first dose of study intervention up to 9 weeks after the last dose of study intervention (maximum duration: 49 weeks)
- Number of Participants With Treatment-emergent Adverse Events of Special Interest (AESI)Time frame: From first dose of study intervention up to 9 weeks after the last dose of study intervention (maximum duration: 49 weeks)
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Investigational Site Number 3920005
Ishikawa, Japan
Investigational Site Number 3920004
Kanagawa, Japan
Investigational Site Number 3920003
Osaka, Japan
Investigational Site Number 3920002
Saitama, Japan
Investigational Site Number 3920001
Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.